US4525359A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment for selective weight control
Assignee: Individual
•
Filing: 1982-12-10
•
Granted: 1985-06-25
•
Expires: 2002-12-10
Abstract
Abstract A treatment for accelerating regional weight reduction in humans, wherein an active ingredient encouraging elimination of fatty deposits, preferably a beta adrenergic stimulator or an alpha-2 adrenergic inhibitor, is selectively delivered to a regional fat deposit prior to commencing or during a general weight control program, whereby body weight is preferentially reduced in the selected area. The beta adrenergic stimulator, preferably isoproterenol or forskolin, or the alpha-2 adrenergic inhibitor, preferably yohimbine, or combinations thereof may be delivered by any means accomplishing specific delivery to the selected area, including injection, implantation, and topical application to the skin as in an ointment or creme.
Inventors
- 👤 Frank L. Greenway, III
- 👤 George A. Bray
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:12
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/41; A61K31/435; A61K31/47; A61K31/475; A61K31/48; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K8/00; A61K8/18; A61K8/30; A61K8/40; A61K8/41; A61K8/49; A61K8/494; A61K8/4953; A61K8/4973; A61K8/498; A61K9/0019; A61P; A61P3/00; A61P3/06; A61Q; A61Q19/00; A61Q19/06
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
66 words
A process for achieving a selective reduction in body weight, comprising the steps of: delivering specifically to the portion of the body where weight reduction is sought a therapeutically effective amount of a beta adrenergic stimulator and accomplishing a general weight loss program whereby an acceleration of weight loss is achieved from the portion of the body to which the beta adrenergic stimulator was selectively delivered.
Claim 2
Dependent Claim
66 words
A process for achieving a selective reduction in body weight, comprising the steps of: delivering specifically to the portion of the body where weight reduction is sought a therapeutically effective amount of a beta adrenergic stimulator and accomplishing a general weight loss program whereby an acceleration of weight loss is achieved from the portion of the body to which the beta adrenergic stimulator was selectively delivered.
Claim 3
Dependent Claim
13 words
The process of claim 1, wherein said delivery step is achieved by injection.
Claim 4
Dependent Claim
16 words
The process of claim 1, wherein the beta adrenergic stimulator is specifically delivered to the thighs.
Claim 5
Dependent Claim
20 words
The process of claim 1, wherein said delivery step is achieved by topical application to the surface of the skin.
Claim 6
Dependent Claim
12 words
The process of claim 1, wherein the beta adrenergic stimulator is isoproterenol.
Claim 7
Dependent Claim
35 words
The process of claim 1, wherein the beta adrenergic stimulator introduced specifically into the portion of the body where weight reduction is sought is selected from the group consisting of theophylline, isoproterenol, forskolin and epinephrine.
Claim 8
Dependent Claim
46 words
A process for accelerated reduction of a regional fat deposit present in a selected portion of the body, comprising the steps of: introducing specifically into the regional fat deposit a therapeutically effective amount of a beta adrenergic stimulator and undergoing a program of general weight reduction.
Claim 9
Dependent Claim
46 words
A process for accelerated reduction of a regional fat deposit present in a selected portion of the body, comprising the steps of: introducing specifically into the regional fat deposit a therapeutically effective amount of a beta adrenergic stimulator and undergoing a program of general weight reduction.
Claim 10
Dependent Claim
22 words
The process of claim 6, wherein the beta adrenergic stimulator is selected from the group consisting of theophylline, isoproternol, forskolin and epinephrine.
Claim 11
Dependent Claim
13 words
The process of claim 6, wherein said introducing step is accomplished by injection.
Claim 12
Dependent Claim
20 words
The process of claim 6, wherein said introducing step is accomplished by topical application to the surface of the skin.
Claim 13
Dependent Claim
49 words
A process for accelerating the reduction of regional fat deposits in a person undergoing a program of treatment for an overweight condition, comprising the step of: delivering specifically to the portion of the person's body where weight reduction is sought a therapeutically effective amount of a beta adrenergic stimulator.
Claim 14
Dependent Claim
49 words
A process for accelerating the reduction of regional fat deposits in a person undergoing a program of treatment for an overweight condition, comprising the step of: delivering specifically to the portion of the person's body where weight reduction is sought a therapeutically effective amount of a beta adrenergic stimulator.
Claim 15
Dependent Claim
14 words
The process of claim 11, wherein said step of delivering is accomplished by injection.
Claim 16
Dependent Claim
20 words
The process of claim 11, wherein said step delivering is accomplished by topical application to the surface of the skin.
Claim 17
Dependent Claim
29 words
The process of claim 11, wherein the portion of the body where weight reduction is sought is the thighs, and the beta adrenergic stimulator is delivered to the thighs.
Claim 18
Dependent Claim
29 words
The process of claim 11, wherein the portion of the body where weight reduction is sought is the legs, and the beta adrenergic stimulator is delivered to the legs.
Claim 19
Dependent Claim
22 words
The process of claim 11, wherein the beta adrenergic stimulator is selected from the group consisting of theophylline, isoproterenol, forskolin, and epinephrine.
References Cited (Backward Citations)
US2493471A
Cited
US3422196A
Cited
US3074847A
Cited
US3808317A
Cited
US3818101A
Cited
US4288433A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-06-24 | 1988-12-24 | 1989-06-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-06-24 | 1992-12-24 | 1993-06-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-06-24 | 1996-12-24 | 1997-06-25 | $7700.00 | Window Closed / Lapsed |